Camptothecins in cancer therapy

Author(s)

• Adame, Val R.
• Burke, Thomas G.

Bibliographic Information

Camptothecins in cancer therapy

edited by Val R. Adams and Thomas G. Burke

（Cancer drug discovery and development）

Humana Press, c2005

• : hard
• : e-ISBN

Note

Includes bibliographies and index

Description and Table of Contents

Volume

: hard ISBN 9781588290274

Description

A critical review our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance.

Table of Contents

Part I: Biochemistry, Pharmacology, and Chemistry Mechanism of Action of Topoisomerase 1 Poisons Leroy F. Liu and Shyamal D. Desai Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage Alex B. Burgin, Jr., Michael D. Feese, Bart L. Staker, and Lance Stewart Inhibitors of Topoisomerase I Function Sidney M. Hecht Cytotoxic Mechanisms of the Topoisomerase 1 Inhibitors Yves G. Pommier, Juana Barcelo, Takahisa Furuta, Haruyuki Takemura, Olivier Sordet, and ZhiYong Liao Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage Robert C. A. M. van Waardenburg and Mary-Ann Bjornsti Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs Aarti S. Juvekar, Joyce Thompson, Clinton F. Stewart, and Peter J. Houghton Mechanisms of Resistance to Camptothecins Zeshaan A. Rasheed and Eric H. Rubin Recent Advances in Camptothecin Drug Design and Delivery Strategies Thomas G. Burke, Tian-Xiang Xiang, Bradley D. Anderson, and Lori J. Latus Part II: Clinical Perspectives Clinical Experience With 9-Aminocamptothecin: Lessons for New Drug Development Chris H. Takimoto Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin) Hilary Hewes, Judith A. Smith, and Claire Verschraegen Irinotecan: Current Clinical Status and Pharmacological Aspects Laurent P. Rivory Clinical Experience With Topotecan Aimee K. Bence and Val R. Adams The Clinical Development of Lurtotecan: Experience With Water-Soluble and Liposomal Forms Keith T. Flaherty, James P. Stevenson, Christopher J. Twelves, and Peter J. O'Dwyer Preclinical and Clinical Development of Exatecan (DX-8951f): A Hexacyclic Camptothecin Analog Eric K. Rowinsky Camptothecins in the Treatment of Primary Brain Tumors Clinton F. Stewart,Markos Leggas, and Henry S. Friedman Camptothecins in the Treatment of Lung Cancer Pankaj Kumar, Missak Haigentz, Jr., Jorge Gomez, and Roman Perez-Soler Use of Camptothecins in the Treatment of Leukemia and Related Disorders Benjamin M. F. Mow and Scott H. Kaufmann Index

Volume

: e-ISBN ISBN 9781592598663

Description

The text provides an up to the minute summary of what is known today about the biochemistry and pharmacology of the camptothecins. The chapter that covers this subject includes a discussion of the mechanism of action of topoisomerase I, and a review of the means by which camptothecins poison this enzyme. The use of animal models in defining the anticancer potential of camptothecins and a discussion of camptothecin resistance is included. Part two of the text is devoted to a review of new analogue development as well as drug delivery issues that are aimed at optimizing the anticancer activities of camptothecins. In the last section of the book the clinical perspective is presented. The authors have included current summaries on each of the members of the camptothecin families that have been studied in the clinic. Along with these reviews discussions of the potential use of camptothecins in a variety of different cancers has been included.

Table of Contents

• Part I. Biochemistry, Pharmacology, and Chemistry
• Mechanism of Action of Topoisomerase I Poisons
• Leroy F. Liu and Shyamal D. Desai
• Crystallographic Insight into the Mechanism of Drug-Induced Topoisomerase I DNA damage
• Alex B. Burgin, Jr., Bart L. Staker, and Lance Stewart
• Inhibitors of Topoisomerase I Function
• Sidney M. Hecht
• Cytotoxic Mechanisms of the Topoisomerase I Inhibitors
• Yves Pommier, Juana Barcelo, Takahisa Furuta, Haruyuki Takemura, Olivier Sordet, and ZhiYong Liao
• Biochemical and Genetic Analyses of DNA Topoisomerase I-Mediated DNA Damage
• Robert C. A. M. van Waardenburg and Mary-Ann Bjornsti
• Preclinical Models for Evaluating Topoisomerase-I Targeted Drugs
• Aarti S. Juvekar, Joyce Thompson, Clinton F. Stewart, and Peter Houghton
• Mechanisms of Resistance to Camptothecins
• Zeshaan A. Rasheed and Eric H. Rubin
• Recent Advances in Camptothecin Drug Design and Delivery Strategies
• Thomas G Burke, Tian-Xiang Xiang, Bradley D. Anderson, and Lori J. Latus
• Part II. Clinical Perspectives
• Clinical Experience with 9-Aminocamptothecin: Lessons for New Drug Development
• Chris H. Takimoto
• Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin)
• Hilary Hewes, Judith A. Smith, and Claire Verschraegen
• Irinotecan: Current Clinical Status and Pharmacological Aspects
• Laurent P. Rivory
• Clinical Experience with Topotecan
• Aimee K. Bence and Val R. Adams
• The Clinical Development of Lurtotecan: Experience with Water-Soluble and Liposomal Forms
• Keith T. Flatherty, James P. Stevenson, Christopher J. Twelves, and Peter J. O'Dwyer
• Preclinical and Clinical Development of DX-8951f (Exatecan Mesylate), a Hexacyclic Camptothecin Analog
• Eric K. Rowinsky
• Camptothecins in the Treatment of Primary Brain Tumors
• Clinton F. Stewart, Markos Leggas, and Henry S. Friedman
• Camptothecins in the Treatment of Lung Cancer
• Pankaj Kumar, Missak Haigentz, Jr., Jorge Gomez, and Roman Perez-Soler
• 'Use of Camptothecins in the Treatment of Leukemia and Related Disorders
• Bejamin M. F. Mow and Scott H. Kaufmann

by "Nielsen BookData"

Details

• NCID: BA74772513
• ISBN:
  • 1588290271
  • 1592598668
• LCCN: 2004013542
• Country Code: us
• Title Language Code: eng
• Text Language Code: eng
• Place of Publication: Totowa, N.J.
• Pages/Volumes: xiii, 460 p.
• Size: 24 cm
• Classification:
  • LCC : RC271.C35
  • NLM : QV 269
  • DC22 : 616.99/4061
• Subject Headings:
  • LCSH : Camptothecin
  • LCSH : Cancer -- Chemotherapy
  • MESH : Camptothecin -- therapeutic use
  • MESH : Neoplasms -- drug therapy
  • MESH : Antineoplastic Agents, Phytogenic -- therapeutic use
  • MESH : Camptothecin -- analogs & derivatives
  • MESH : Camptothecin -- pharmacology
• Parent Bibliography ID:
  • BA36585533